Short-course of Oral Miltefosine for Treatment of Visceral Leishmaniasis

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2000 Oct 26

PMID 11049800

Citations 42

Authors

S Sundar

A Makharia

D K More

G Agrawal

A Voss

C Fischer

P Bachmann

H W Murray

Affiliations

Soon will be listed here.

Abstract

A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.

Citing Articles

In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.

Mano C, Kongkaew A, Tippawangkosol P, Junkum A, Siriyasatien P, Jariyapan N Parasitol Res. 2023; 122(12):3027-3035.

PMID: 37796293 DOI: 10.1007/s00436-023-07992-3.

Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with .

Olias-Molero A, Botias P, Cuquerella M, Garcia-Cantalejo J, Barcia E, Torrado S Antibiotics (Basel). 2023; 12(2).

PMID: 36830274 PMC: 9952363. DOI: 10.3390/antibiotics12020362.

Impact of Genetic Diversity and Genome Plasticity of spp. in Treatment and the Search for Novel Chemotherapeutic Targets.

Santi A, Murta S Front Cell Infect Microbiol. 2022; 12:826287.

PMID: 35141175 PMC: 8819175. DOI: 10.3389/fcimb.2022.826287.

Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant With Increased Efficacy.

Mukherjee S, Pradhan S, Ghosh S, Sundar S, Das S, Mukherjee B Front Cell Infect Microbiol. 2020; 10:595415.

PMID: 33240825 PMC: 7683767. DOI: 10.3389/fcimb.2020.595415.

The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis.

Tanzifi A, Khoshi A, Emami S, Sarvi S, Sharif M, Montazeri M Parasitol Res. 2020; 119(4):1371-1380.

PMID: 31970471 DOI: 10.1007/s00436-020-06601-x.